New clinical study with MenaQ7, VitaK-CAC

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

New clinical study with MenaQ7: NattoPharma is co-sponsor in an intervention study, VitaK-CAC, investigating the effects of natural vitamin K2 supplementation on coronary arterial calcification.

NattoPharma is proud to announce that health benefits of our MenaQ7 product now will be studied in an impressive clinical trial, especially in the light of our patent portfolio where cardiovascular health is of particular importance. The study will be performed at the Department of Internal Medicine of the Maastricht University Medical Centre in the Netherlands, in cooperation with Dutch Heart Foundation.

Background
Coronary heart disease is the number one cause of death in the world according to the WHO and significant resources are allocated to handle the care of patients suffering from cardiovascular disease. Coronary Artery Calcification (CAC) occurs in coronary atherosclerosis and is a strong, independent cardiovascular risk factor and is demonstrated to be a powerful predictor of cardiovascular events.

Study design
The current study will address the important issue of slowing CAC progression by the use of vitamin K2 supplementation in a double-blind, placebo-controlled, randomized trial with one treatment group receiving MenaQ7 and one group receiving placebo. The study population will consist of 180 patients and the objective is to test the hypothesis that Vitamin K2 supplementation in comparison to placebo will slow down CAC-progression after 12 and 24 months in patients with existing CAC. (i.e. will Vitamin K2 supplementation prevent further, rapid progression of CAC). The duration of the entire project will be approximately 4 years.

Use of food supplements to improve health parameters
Earlier studies in humans demonstrate that a high dietary intake of Vitamin K is associated with a lower cardiovascular risk and a lesser degree of CAC. During the last 15 years, vitamin K supplements have been used in many short and long term clinical intervention studies, both in adults and in children with no adverse events reported. The effects of Vitamin-K2 supplementation on the progression of CAC have however not yet been studied in humans in a controlled clinical trial.

Recently appointed Vice President of Research and Development at NattoPharma, Dan Edwall says "The planning for this important study has been initiated by previous management in NattoPharma and we are very happy and proud that health benefits of our MenaQ7 product will now be studied in this impressive clinical trial, especially in the light of our patent portfolio where cardiovascular health is of particular importance."

For more information:
CEO Peter Carlsson
Phone: +47 950 49 906

 # # #

About MenaQ7
MenaQ7 provides natural vitamin K2 as a fermentation extract whereby vitamin K2 is manufactured using bascillus subtilis natto. This process has the capacity of producing the highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7). MenaQ7 is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending.

For more information on the health benefits of MenaQ7, please visit www.menaq7.com  

About NattoPharma
NattoPharma, Norway is the exclusive international supplier of MenaQ7, the natural Vitamin K2. NattoPharma has entered into a multi-year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the exciting marketplace for functional food and health food supplements.

For more information, please visit www.nattopharma.com

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.

Subscribe

Documents & Links